PTC Therapeutics Forecasts Up to $800 Million in 2025 Revenues

Published 1 days agoPTCT

PTC Therapeutics Forecasts Up to $800 Million in 2025 Revenues

PTC Therapeutics has announced its financial expectations for 2025, projecting total revenues between $600 million and $800 million. This forecast includes income from existing products, new product launches, and royalties from Evrysdi. As part of its broader business strategy, the company is pursuing a robust product pipeline expected to support these revenue goals.

The pharmaceutical company's anticipated expenses for 2025 are substantial, with expected GAAP R&D and SG&A costs ranging between $805 million and $835 million. In non-GAAP terms, which exclude estimated non-cash stock compensation of $75 million, these expenses are expected to be between $730 million and $760 million. Reuters reported that these figures reflect PTC's substantial investment in research and development and its strategic operational initiatives.

PTC's recent collaboration with Novartis marks a significant achievement. Closing a licensing agreement for the PTC518 Huntington's disease program has provided an immediate $1.0 billion boost, with further milestone payments of up to $1.9 billion possible. Additionally, PTC stands to gain a 40% profit share from U.S. sales and enjoy tiered royalties outside the U.S. This partnership has significantly improved PTC's financial standing, leaving the company with a cash position over $2.0 billion as of January 2025, thus positioning it strongly for future endeavors.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Paramount Global Surpasses Earnings Expectations with Streaming Growth

Paramount Global Surpasses Earnings Expectations with Streaming Growth

5 minutes agoPARA

Paramount Global has delivered a robust first-quarter performance in 2025, significantly propelled by its direct-to-consumer streaming services and original programming. The company reported $7.19 billion in revenue, outstripping analysts' expectations of $7.09 billion, and achieved an adjusted profit of 29 cents per share, surpassing the projected 25 cents, as detailed in a report by Reuters. Key to Paramount's success was the 9% revenue increase in its direct-to-consumer segment, which includes platforms like Paramount+, BET, and Pluto TV. This growth was bolstered by original content and popular post-theatrical releases such as "Gladiator II." However, subscriber growth for Paramount+ fell slightly short of forecasts, with 1.5 million new subscribers versus an expected 1.66 million. The filmed entertainment segment also saw a 4% growth, achieving $627 million in revenue. Adding to its strategic maneuvers, Paramount is set to release "Mission Impossible - The Final Reckoning," which is anticipated to further enhance revenue streams. The company has also extended the timeline for its merger with Skydance Media, a deal worth $8 billion, by 90 days with closure expected within the first half of the year. Such initiatives underscore Paramount's dedication to leveraging original content and streaming capabilities to maintain its competitive edge in the rapidly shifting media industry.

Tetra Tech Achieves Record Revenue in Q1, Raises 2025 Outlook

Tetra Tech Achieves Record Revenue in Q1, Raises 2025 Outlook

21 minutes agoTTEK

Tetra Tech, Inc. has reported outstanding financial results for the first quarter of fiscal year 2025, showcasing a record revenue of $1.42 billion, representing a 16% increase from the previous year. Net revenue also reached new heights at $1.20 billion, an 18% rise compared to last year, according to Tetra Tech's official report. The company's operating income totaled $23 million, with an adjusted operating income increasing by 24% year-over-year to $138 million. Although the earnings per share (EPS) were recorded at $0.00, the adjusted EPS saw a substantial 25% year-over-year growth, reaching $0.35. In addition, Tetra Tech's backlog hit a record $5.44 billion, a 15% increase year-over-year, demonstrating a strong demand for its services. In light of these results, Tetra Tech has increased its full-year fiscal 2025 guidance, projecting net revenue between $4.365 billion and $4.765 billion and an adjusted EPS of $1.37 to $1.52. The company is focusing on expanding its high-end services in areas such as coastal flood protection, water supply security, and the digital upgrade of water infrastructure, as highlighted by Business Wire. These strategies position Tetra Tech well to capitalize on the growing demand for water and digital solutions.

Nu Skin to Launch Prysm iO™, Projects Strong 2025 Revenue

Nu Skin to Launch Prysm iO™, Projects Strong 2025 Revenue

51 minutes agoNUS

Nu Skin Enterprises is set to launch its new intelligent wellness device, Prysm iO™, later this year. The company aims for this launch to bolster growth in its nutrition segment, a strategic move expected to attract more consumers and enhance its market presence. This announcement was highlighted by investing.com, which showcased the company's efforts to innovate within its product offerings. In addition, Nu Skin provided revenue projections for 2025, with expectations to generate between $345 million and $365 million in the first quarter. For the entire year, the company targets a revenue range of $1.48 billion to $1.62 billion. Following this optimistic forecast, shares of Nu Skin surged by 16.2%, reflecting market confidence in the company's financial health and strategic planning. Nu Skin has expressed a focus on strengthening its core business activities and expanding in emerging markets, particularly in Latin America. Moreover, the company anticipates adjusted earnings per share between $0.90 and $1.30 for 2025, not accounting for gains from the sale of Mavely, according to nasdaq.com. These initiatives underscore Nu Skin's commitment to enhancing both its product offerings and overall financial performance.

McKesson Maintains Steady Course with Medical-Surgical Supply Segment

McKesson Maintains Steady Course with Medical-Surgical Supply Segment

As of May 8, 2025, there is no current indication that McKesson Corporation intends to spin off its medical-surgical supply business. The last major transaction involving this segment dates back to October 2006, when McKesson sold its acute-care medical and surgical supply distribution business to Owens & Minor, Inc. Despite a lack of recent spin-off plans, McKesson's Medical-Surgical Solutions segment continues operations, servicing a range of healthcare facilities with medical supplies and solutions. Notably, in March 2023, McKesson Medical-Surgical Government Solutions secured a five-year U.S. Department of Veterans Affairs Federal Supply Schedule contract. This development highlights McKesson's active role in the healthcare supply chain. Overall, McKesson appears to be integrating its medical-surgical supply business within its larger operational structure, as no recent announcements have been made about separating this segment. The company's focus remains on leveraging its strengths to maintain its position in the healthcare industry.